Overview of the Inflammatory Bowel Disease (IBD) Treatment Market
The inflammatory bowel disease treatment market is expected to grow from USD 19.91 billion in 2023 to approximately USD 33.19 billion by 2032, with a compound annual growth rate (CAGR) of 5.5% from 2024 to 2032.
Download a sample of this report @ https://www.towardshealthcare.com/personalized-scope/5149
Key Market Highlights:
- Crohn’s Disease held the largest market share by disease type, accounting for over 61% in 2023.
- TNF Inhibitors dominated the drug classes with a 32% market share in 2023.
- Retail Pharmacies led the market distribution channels with a 36% market share in 2023.
Understanding Inflammatory Bowel Disease (IBD)
Inflammatory Bowel Disease (IBD) includes two primary conditions: Crohn’s disease and ulcerative colitis. These are chronic conditions that cause inflammation in the digestive tract.
- Crohn’s Disease: Characterized by inflammation that can affect any part of the gastrointestinal tract, primarily impacting the small intestine but can also affect the large intestine and, in rare cases, the upper gastrointestinal tract.
- Ulcerative Colitis: Involves inflammation and ulceration in the lining of the large intestine (colon) and rectum.
Increasing Prevalence of IBD Globally
The prevalence of IBD, including Crohn’s disease and ulcerative colitis, is on the rise globally, impacting millions of lives and posing significant challenges to healthcare systems. Factors contributing to this increase include:
- Diet: A Western diet, high in processed foods, refined carbohydrates, and unhealthy fats, is believed to affect gut microbiota and alter immune responses.
- Smoking: Cigarette smoking, particularly due to nicotine’s impact, is linked to an increased risk of developing Crohn’s disease.
- Lifestyle: Sedentary lifestyles and urbanization are associated with higher rates of IBD, possibly due to environmental factors.
IBD Prevalence in Canada
Canada has one of the highest rates of IBD globally. In 2023, it was estimated that 825 per 100,000 Canadians live with IBD, equating to 322,600 people:
- Crohn’s Disease: 410 cases per 100,000 people
- Ulcerative Colitis and IBD-U (Inflammatory Bowel Disease of Uncertain Location): 414 cases per 100,000 people
Projections suggest the prevalence of IBD in Canada will rise to 1.08% by 2035, potentially affecting 470,000 Canadians.
Pediatric and Adult Trends in IBD
There is a noticeable rise in pediatric-onset IBD. Data from the National Institute of Health estimates the incidence of pediatric IBD to increase from 13.9 per 100,000 children in 2014 to 18.0 per 100,000 by 2035, with an annual increase rate of 1.23%.
Conversely, the incidence of IBD among adults and seniors (64 and older) remains steady and is expected to continue at the same rate over the next decade.
The GEM Project and Research Efforts
Crohn’s and Colitis Canada, a leading health charity, has invested over $145 million in research since 1974, focusing on genetics, gut microbiota, inflammation, and cell repair. The Genetic, Environmental, and Microbial (GEM) Project is one of their key initiatives, aiming to uncover the factors that cause IBD. Recent research funded by Crohn’s and Colitis Canada includes studies on immune mechanisms, links between Crohn’s disease and Type-2 diabetes, and the use of new lab models to understand ulcerative colitis.
Government and Non-Profit Initiatives Driving Market Growth
Government agencies and non-profit organizations are increasingly investing in innovative IBD treatments:
- IBD Ventures Program (2024): Funded three companies to accelerate the development of therapies aimed at increasing remission rates and improving the quality of life for IBD patients.
- IBD Aware (2024): A new wearable device developed for non-invasive, continuous monitoring of IBD, funded by Crohn’s & Colitis Foundation and developed in collaboration with EnLiSense CCM and Icahn School of Medicine.
Technological Innovations and New Product Approvals
- Rinvoq (upadacitinib): Approved in April 2023 by the European Commission as the first oral Janus Kinase (JAK) inhibitor for moderate to severe Crohn’s disease.
- Implantable Temperature Sensor (2024): Developed by Northwestern University researchers, this wireless, implantable sensor provides real-time inflammation monitoring for Crohn’s disease patients.
Market Dynamics and Future Outlook
- TNF Inhibitors: Medications like Remicade, Humira, and Enbrel have revolutionized the management of Crohn’s disease by offering safer and more effective treatments. Despite the rise of biosimilar alternatives, TNF inhibitors are expected to remain a preferred choice due to their proven efficacy and safety profile.
- Geographical Insights: North America holds the largest share of the IBD treatment market, followed by Europe, due to the higher prevalence of the disease and associated healthcare costs. The prevalence in Asia and Africa remains relatively low compared to Western regions.
Inflammatory Bowel Disease Treatment Market Companies
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited.
- Pfizer Inc.
- Biogen
- Novartis AG
- Eli Lilly and Company
- UCB S.A.
- CELLTRION INC.
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
Inflammatory Bowel Disease Treatment Market Segments
(**We also provide cross-sectional analysis in market segments)
By Type
- Crohn’s Disease
- Ulcerative Colitis
By Drug Class
- Corticosteroids
- Aminosalicylates
- TNF Inhibitors
- IL Inhibitors
- JAK Inhibitors
- Anti-Integrin
- Others
By Route of Administration
- Oral
- Injectable
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Geography
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- South America
Read Also: https://www.healthcarewebwire.com/precision-oncology-market-size/
Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/inflammatory-bowel-disease-treatment-market-sizing
To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5149
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
